{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T12:53:08Z","timestamp":1774183988352,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clon.2019.09.055","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T17:13:38Z","timestamp":1570727618000},"page":"250-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions"],"prefix":"10.1016","volume":"32","author":[{"given":"R.","family":"Rulach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"McLoone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lumsden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Macphee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Omand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2019.09.055_bib1","author":"Cancer Research UK"},{"key":"10.1016\/j.clon.2019.09.055_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/thx.2003.018044","article-title":"Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer","volume":"59","author":"Janssen-Heijnen","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.clon.2019.09.055_bib4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2019.09.055_bib5","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/annonc\/mds081","article-title":"Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands","volume":"23","author":"Haasbeek","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib6","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2011.04.034","article-title":"Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage i non-small-cell lung cancer? A meta-analysis","volume":"81","author":"Zhang","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.09.055_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2014.10.002","article-title":"Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer","volume":"91","author":"Koshy","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.09.055_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib15","series-title":"UK SABR consortium guidelines version 6.1","first-page":"44","year":"2019"},{"key":"10.1016\/j.clon.2019.09.055_bib16","doi-asserted-by":"crossref","first-page":"20150036","DOI":"10.1259\/bjr.20150036","article-title":"LungTech, an EORTC phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective","volume":"88","author":"Adebahr","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clon.2019.09.055_bib17","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0167-8140(19)30481-5","article-title":"OC-0061 EORTC 22113-8113 Lungtech trial on SBRT of central lung tumors","volume":"133","author":"Adebahr","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijrobp.2015.10.040","article-title":"Primary study endpoint analysis for NRG Oncology\/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC)","volume":"94","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib19","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1378\/chest.128.4.2490","article-title":"Clinical prediction model to characterize pulmonary nodules","volume":"128","author":"Herder","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.clon.2019.09.055_bib20","series-title":"Basic clinical radiobiology","first-page":"78","article-title":"Tumour growth and response to radiation","author":"Zips","year":"2009"},{"key":"10.1016\/j.clon.2019.09.055_bib21","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2014.08.008","article-title":"Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy","volume":"90","author":"Modh","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.09.055_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2019.09.055_bib23","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/JTO.0b013e31822e71d8","article-title":"Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer","volume":"6","author":"Haasbeek","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib24","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.jtho.2016.11.369","article-title":"OA24.05 The Nordic HILUS-Trial - First report of a phase II trial of SBRT of centrally located lung tumors","volume":"12","author":"Lindberg","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2015.09.028","article-title":"Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and long-term clinical outcomes","volume":"117","author":"Tekatli","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2019.09.055_bib27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2017.11.022","article-title":"Normal tissue complication probability modeling of pulmonary toxicity after stereotactic and hypofractionated radiation therapy for central lung tumors","volume":"100","author":"Tekatli","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2019.09.055_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519304340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519304340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:47:31Z","timestamp":1760543251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655519304340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0936655519304340"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2019.09.055","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2019.09.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}